Excision BioTherapeutics is a clinical-stage biotechnology company developing CRISPR-based in vivo gene-editing therapies aimed at curing serious viral infectious diseases. Its programs apply multiplexed CRISPR editing delivered via AAV vectors to excise viral DNA from the host genome, led by EBT-101, an investigational one-time therapy for HIV. - View it on GitHub